Dr. Lal PathLabs to buy 70% of SN Genelab in deal valued at about Rs 200 crore
Dr. Lal PathLabs will acquire a 70% stake in genomics diagnostics firm SN Genelab for up to Rs 168 crore in cash plus performance-linked earn-outs capped at Rs 31.5 crore. The transaction, expected to close by November 30, 2026, will make SN Genelab a subsidiary and broaden Lal PathLabs’ advanced genomics portfolio.
What happened
Dr. Lal PathLabs will acquire 70% of Gujarat-based genomics diagnostics firm SN Genelab for up to about Rs 200 crore, including earn-out payments. The
Key facts
- 70% stake
- Up to Rs 168 crore cash consideration
- Rs 31.5 crore performance-linked earn-out cap
- Approximately Rs 200 crore total deal value
- SN Genelab FY2025 turnover: Rs 53.36 crore
What changed
Dr. Lal PathLabs will acquire 70% of Gujarat-based genomics diagnostics firm SN Genelab for up to about Rs 200 crore, including earn-out payments. The acquisition will make SN Genelab a subsidiary and expand Dr. Lal PathLabs’ advanced genomics diagnostic-services portfolio.
Why this matters
Dr. Lal PathLabs can expand its premium genomics testing menu and referral-network capabilities by integrating SN Genelab as a subsidiary while managing operational alignment through the 2026 close.
What to watch
- Regulatory and shareholder approvals, closing progress and any revision to the stated November 30, 2026 completion target.
- Disclosure of SN Genelab's revenue growth, EBITDA profile, test mix, customer concentration and earn-out performance conditions.
- Post-close rollout of genomics tests across Dr. Lal PathLabs collection centers and digital booking channels.
- Growth in oncology, reproductive, prenatal and rare-disease test volumes versus routine diagnostics.
- Management commentary on acquisition-related costs, margin impact, cross-selling and turnaround time.